In vitro studies demonstrated that USP22 overexpression markedly enhanced proliferation, migration, and invasion capacities in CCA cell lines (RBE, HCCC-9810), accompanied by EMT induction (E-cadherin downregulation/vimentin upregulation), whereas USP22 knockdown produced opposing effects, validating its oncogenic role. This evidence concerns the gene USP22 and cholangiocarcinoma.